Format

Send to

Choose Destination
Pediatr Blood Cancer. 2012 May;58(5):815-8. doi: 10.1002/pbc.23290. Epub 2011 Aug 16.

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.

Author information

1
A.I. duPont Hospital for Children, Wilmington, Delaware 19803, USA. eakolb@nemours.org

Abstract

RO4929097 is a potent and selective inhibitor of γ-secretase and as a result is able to inhibit Notch pathway signaling. The activity of RO4929097 was evaluated against the in vivo panels of the Pediatric Preclinical Testing Program (PPTP). RO4929097 induced significant differences in event-free survival (EFS) distribution compared to control in 6 of 26 (23%) of the evaluable solid tumor xenografts and in 0 of 8 (0%) of the evaluable ALL xenografts. The most consistent tumor growth delay effects were noted in the osteosarcoma panel. RO4929097 at the dose and schedule evaluated demonstrated little antitumor activity against childhood cancer xenografts.

PMID:
22052798
PMCID:
PMC3276746
DOI:
10.1002/pbc.23290
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center